Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: resu
- PDF / 569,081 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 15 Downloads / 187 Views
ORIGINAL ARTICLE
Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry Nikita R. Bhatt1 · Niall F. Davis2 · W. P. Witjes3 · A. Bjartell3,4 · C. Caris3 · A. Patel5 · A. de la Taille6 · Mark Speakman7 · Luis Martínez‑Piñeiro8 · A. Tubaro9 Received: 22 July 2020 / Accepted: 1 October 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Background To use the European Association of Urology Research Foundation (EAURF) registry data to determine the proportion of contemporary Lower Urinary Tract Symptoms associated with Benign Prostatic Enlargement (LUTS/BPE) patients prescribed phytotherapy, and to determine their subjective quality of life and clinical progression responses. Methods This was a prospective multicenter multinational observational registry study, conducted over 2 years. Men ≥ 50 years seeking LUTS/BPE were divided at baseline into two cohorts, presently/recently untreated patients (PUP) commencing pharmacotherapy at baseline and presently/recently treated patients (c-PTP) continuing previously received pharmacotherapy, with 24-month follow-up (FU). Results Overall, 2175 patients were enrolled with 1838 analyzed. Of the PUP cohort (n = 575), 92 (16%) received phytotherapy and 65 (71%, n = 65/92) completed 24-month FU, with France prescribing 34% (n = 30/89) the highest proportion of phytotherapy among all LUTS/BPE medications. In the c-PTP group (n = 1263), only 69 (5%) patients were using phytotherapy, falling to n = 35/69 (51%) at 24-month FU (highest in France 20% (n = 43/210)). Though defined disease progression occurred in ≤ 20%, with only 1% proceeding to surgical intervention, in both groups, clinically meaningful improvement was lower and symptom persistence was higher in PUP but similar in the treated (c-PTP) patients on phytotherapy compared to the other LUTS/BPE medication. Conclusion Low heterogeneous prescribing rates for phytotherapy were reported in both PUP and c-PTP cohorts over the 24-month FU. Although phytotherapy led to subjective improvements, healthcare practitioners should prescribe them with caution until higher quality evidence and guideline recommendations supporting its use are available. Keywords Guidelines · Medical treatment · Plant extracts · Serona repens · Benign prostatic enlargement
* Nikita R. Bhatt [email protected] 1
6
Department of Urology, Assistance Publique Des Hopitaux de Paris, 54 Av du Mal de Lattre de Tassigny, 94000 Créteil, France
Department of Urology, Queen Elizabeth Hospital King’s Lynn, King’s Lynn, England, UK
7
2
Department of Urology, Beaumont Hospital and Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland
Department of Urology, Taunton and Somerset, NHS Foundation Hospital, Taunton, UK
8
3
EAU Research Foundation, P.O. Box 30016, 6803 AA Arnhem, The Netherlands
Department of Urology, La Paz University Hospital, Madrid, Spain
9
4
Department of Urology, Skane Hospital, L
Data Loading...
